Grant: Doctoral Research Award - PA: Regional Partnerships Program - Saskatchewan
University of Saskatchewan
$52,500.00
Conformation specific targeting of misfolded superoxide dismutase 1 as an immunotherapeutic strategy for Amyotrophic Lateral Sclerosis.
EF 2012-13
Résumé
Amyotrophic Lateral Sclerosis (ALS), also referred to as "Lou-Gehrig's Disease", is the most common motor neuron disease. ALS is characterized by a rapidly progressive degeneration of motor neurons, leading to a loss of muscle function, which often results in death within 1-5 years of onset. There is currently no cure for ALS and symptomatic therapy remains the most beneficial, therefore there is an urgent need for new therapies. A key cellular enzyme, SOD1, has been implicated in the pathology of ALS. This enzyme, when functioning normally, is responsible for neutralizing free radicals in the cell. In ALS, this enzyme misfolds and goes rogue, taking on new functions that are toxic, specifically to motor neurons responsible for controlling voluntary muscle contraction. The SOD1 form responsible for disease pathology can be distinguished from normal SOD1 by differences in protein structure. These subtle differences can be recognized by antibodies enabling the neutralization of the toxic effects of this rogue protein without disrupting the properly functioning protein.
Our objective is to design vaccines capable of generating antibodies that can effectively neutralize the toxicity of misfolded SOD1 in the CNS. We aim to investigate the ability of this treatment strategy to significantly delay the onset of clinical symptoms and/or to increase life expectancy, specifically, by increasing motor neuron survival through the reduction of misfolded SOD1 deposits. This project encompasses the preliminary research and development stages for a potential treatment of the devastating disease ALS, which currently lacks an effective therapy. The treatment methodology to be investigated can be applied to other diseases where protein misfolding has been implicated, including Parkinson's and Alzheimer's disease.
Programme
Doctoral Research Award - PA: Regional Partnerships Program - Saskatchewan
Bénéficiaire
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
277273
Name
Marciniuk Kristen
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Saskatchewan Health Research Foundation
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Conformation specific targeting of misfolded superoxide dismutase 1 as an immunotherapeutic strategy for Amyotrophic Lateral Sclerosis.
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$52,500
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA: Regional Partnerships Program - Saskatchewan
Keyworddelim
Amyotrophic Lateral Sclerosis; Conformation Specific Antibodies; Immunotherapy; Peptide Epitope Optimization; Protein Misfolding; Self-Epitope; Sod1; Vaccine Design
Abstract
Amyotrophic Lateral Sclerosis (ALS), also referred to as "Lou-Gehrig's Disease", is the most common motor neuron disease. ALS is characterized by a rapidly progressive degeneration of motor neurons, leading to a loss of muscle function, which often results in death within 1-5 years of onset. There is currently no cure for ALS and symptomatic therapy remains the most beneficial, therefore there is an urgent need for new therapies. A key cellular enzyme, SOD1, has been implicated in the pathology of ALS. This enzyme, when functioning normally, is responsible for neutralizing free radicals in the cell. In ALS, this enzyme misfolds and goes rogue, taking on new functions that are toxic, specifically to motor neurons responsible for controlling voluntary muscle contraction. The SOD1 form responsible for disease pathology can be distinguished from normal SOD1 by differences in protein structure. These subtle differences can be recognized by antibodies enabling the neutralization of the toxic effects of this rogue protein without disrupting the properly functioning protein.
Our objective is to design vaccines capable of generating antibodies that can effectively neutralize the toxicity of misfolded SOD1 in the CNS. We aim to investigate the ability of this treatment strategy to significantly delay the onset of clinical symptoms and/or to increase life expectancy, specifically, by increasing motor neuron survival through the reduction of misfolded SOD1 deposits. This project encompasses the preliminary research and development stages for a potential treatment of the devastating disease ALS, which currently lacks an effective therapy. The treatment methodology to be investigated can be applied to other diseases where protein misfolding has been implicated, including Parkinson's and Alzheimer's disease.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Marciniuk, Kristen
Approvedterm
3 ans 0 mois
Cihrcontribution2
SPIR~ $52,500~ $0~